Dermatology Medical News about Onychomycosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Onychomycosis and diabetes
Journal of the European Academy of Dermatology and Venereology, 09/17/09

Cathcart S et al. – Terbinafine is an excellent choice in diabetics due to its low risk of drug–drug interaction and proven efficacy against the typical pathogens that cause onychomycosis. Itraconazole, while an effective treatment for onychomycosis, is not a first–choice therapy due to its black–box cardiac warning and numerous drug interactions. Larger studies are needed in diabetics to determine the frequency of candidal nail infections.

<< Previous
Removing Costs From The Health Care Supply Chain: Lessons From...

Next >>
Immune zones in leprosy